Clene Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
CLNN$4.41+0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands, except share amounts)
(Unaudited
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total Stockholders’ Equity (Deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances at December 31, 2023 | 6,421,084 | $1 | $255,913 | $(242,723) | $199 | $13,390 |
| Stock-based compensation expense | — | — | 2,013 | — | — | 2,013 |
| Issuance of common stock upon vesting of restricted stock awards | 543 | — | — | — | — | — |
| Unrealized loss on available-for-sale securities | — | — | — | — | (4) | (4) |
| Foreign currency translation adjustment | — | — | — | — | (55) | (55) |
| Net loss | — | — | — | (11,080) | — | (11,080) |
| Balances at March 31, 2024 | 6,421,627 | $1 | $257,926 | $(253,803) | $140 | $4,264 |
| Exercise of stock options | 12,001 | — | 36 | — | — | 36 |
| Stock-based compensation expense | — | — | 1,951 | — | — | 1,951 |
| Unrealized gain on available-for-sale securities | — | — | — | — | 2 | 2 |
| Foreign currency translation adjustment | — | — | — | — | 28 | 28 |
| Net loss | — | — | — | (6,785) | — | (6,785) |
| Balances at June 30, 2024 | 6,433,628 | $1 | $259,913 | $(260,588) | $170 | $(504) |
| Issuance of common stock | 394,453 | — | 2,036 | — | — | 2,036 |
| Exercise of stock options | 29,089 | — | 88 | — | — | 88 |
| Stock-based compensation expense | — | — | 2,188 | — | — | 2,188 |
| Unrealized gain on available-for-sale securities | — | — | — | — | 1 | 1 |
| Foreign currency translation adjustment | — | — | — | — | 52 | 52 |
| Net loss | — | — | — | (7,986) | — | (7,986) |
| Balances at September 30, 2024 | 6,857,170 | $1 | $264,225 | $(268,574) | $223 | $(4,125) |
| Balances at December 31, 2022 | 3,737,921 | 1 | 196,252 | (193,219) | 203 | 3,237 |
| Issuance of common stock | 161,388 | — | 4,664 | — | — | 4,664 |
| Stock-based compensation expense | — | — | 2,223 | — | — | 2,223 |
| Unrealized gain on available-for-sale securities | — | — | — | — | 14 | 14 |
| Foreign currency translation adjustment | — | — | — | — | 4 | 4 |
| Net loss | — | — | — | (11,770) | — | (11,770) |
| Balances at March 31, 2023 | 3,899,309 | $1 | $203,139 | $(204,989) | $221 | $(1,628) |
| Issuance of common stock | 2,520,145 | — | 40,924 | — | — | 40,924 |
| Issuance of equity-classified warrants | — | — | 4,970 | — | — | 4,970 |
| Stock-based compensation expense | — | — | 2,451 | — | — | 2,451 |
| Issuance of common stock upon vesting of restricted stock awards | 544 | — | — | — | — | — |
| Unrealized gain on available-for-sale securities | — | — | — | — | 6 | 6 |
| Foreign currency translation adjustment | — | — | — | — | (53) | (53) |
| Net loss | — | — | — | (25,143) | — | (25,143) |
| Balances at June 30, 2023 | 6,419,998 | $1 | $251,484 | $(230,132) | $174 | $21,527 |
| Common stock issuance costs | — | — | (20) | — | — | (20) |
| Stock-based compensation expense | — | — | 2,396 | — | — | 2,396 |
| Issuance of common stock upon vesting of restricted stock awards | 543 | — | — | — | — | — |
| Unrealized loss on available-for-sale securities | — | — | — | — | (4) | (4) |
| Foreign currency translation adjustment | — | — | — | — | (81) | (81) |
| Net loss | — | — | — | (2,418) | — | (2,418) |
| Balances at September 30, 2023 | 6,420,541 | $1 | $253,860 | $(232,550) | $89 | $21,400 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.